Pharmaceutical company
Appears in 7 stories
Co-developer and co-commercializer of epcoritamab
AbbVie and Genmab said Monday that adding their bispecific antibody epcoritamab to the R-CHOP chemoimmunotherapy backbone cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma (DLBCL). It is the first phase 3 trial of a bispecific antibody to beat R-CHOP in the frontline setting — a regimen that has anchored treatment for over 20 years.
Updated 4 days ago
Developer of Temab-A
The FDA granted AbbVie's experimental cancer drug Temab-A two breakthrough therapy designations on October 7. One covers colorectal cancer, the other non-small cell lung cancer. The designations speed up development and review for drugs that show early evidence of substantial improvement over existing therapies.
Updated 5 days ago
Owner of zumilokibart; running Phase 3 trials
Patients with moderate to severe atopic dermatitis on the mid-dose of zumilokibart hit 65.9% skin clearance at 16 weeks, versus 23.4% on placebo. AbbVie presented the Phase 2 results as a late-breaker at the European Academy of Dermatology and Venereology congress in Vienna on Sept. 30.
Updated Sep 30
Entered multi-year AI drug discovery collaboration with Iambic
Iambic released Enchant v3 on September 21, 2026: a 41-billion-parameter AI model trained on 4.5 trillion tokens of biomedical data, spanning everything from protein structures to clinical trial records. The same day, AbbVie signed a multi-year deal to use the model across immunology, neuroscience, and oncology.
Updated Sep 21
Co-manufacturer of venetoclax (Venclexta); submitted the supplemental new drug application
On February 20, 2026, the FDA approved venetoclax and acalabrutinib for chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western countries, with roughly 23,000 new American cases each year. In a trial of 867 patients, 77% remained cancer-free at three years.
Updated May 29
Decnupaz sponsor and manufacturer
The FDA approved AbbVie's Decnupaz on May 27 for blastic plasmacytoid dendritic cell neoplasm, an aggressive blood cancer. It strikes an estimated few hundred Americans a year. It's the second drug ever approved for the disease and the first doctors can start in an outpatient clinic.
Updated May 28
Marketing first-approved presbyopia drop Vuity
For 240 years, reading glasses have treated presbyopia—the gradual loss of near vision that affects nearly everyone over 45—unchanged since Benjamin Franklin invented bifocals in 1785. Two billion people worldwide still rely on reading glasses today. On January 29, 2026, the FDA approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for presbyopia.
Updated May 23
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
